Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 4 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Thrombotic Thrombocytopenic Purpura.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Thrombotic Thrombocytopenic Purpura Overview 7
Therapeutics Development 8
Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview 8
Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis 9
Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies 10
Thrombotic Thrombocytopenic Purpura - Therapeutics under Investigation by Universities/Institutes 11
Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Thrombotic Thrombocytopenic Purpura - Products under Development by Companies 15
Thrombotic Thrombocytopenic Purpura - Products under Investigation by Universities/Institutes 16
Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development 17
Ablynx NV 17
Biogen Inc 18
Glenmark Pharmaceuticals Ltd. 19
Hansa Medical AB 20
Kaketsuken K.K. 21
Lee's Pharmaceutical Holdings Limited 22
Octapharma AG 23
Omeros Corporation 24
Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ARC-15105 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BAX-930 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
caplacizumab - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GBR-600 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
OMS-721 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
plasma (human) - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
rituximab - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ZK-001 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Thrombotic Thrombocytopenic Purpura - Dormant Projects 60
Thrombotic Thrombocytopenic Purpura - Product Development Milestones 61
Featured News & Press Releases 61
Oct 11, 2016: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura 61
Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP 61
May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association 62
Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP 63
Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP 64
Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH 64
Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 65
Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting 66
Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab 67
Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 68
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 69
Jul 28, 2011: Initial Observations Of ABLYNX'S PHASE II TTP Program Presented At ISTH Congress 70
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 71
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 71
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2016 8
Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H2 2016 17
Thrombotic Thrombocytopenic Purpura - Pipeline by Biogen Inc, H2 2016 18
Thrombotic Thrombocytopenic Purpura - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 19
Thrombotic Thrombocytopenic Purpura - Pipeline by Hansa Medical AB, H2 2016 20
Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken K.K., H2 2016 21
Thrombotic Thrombocytopenic Purpura - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 22
Thrombotic Thrombocytopenic Purpura - Pipeline by Octapharma AG, H2 2016 23
Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corporation, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Thrombotic Thrombocytopenic Purpura - Dormant Projects, H2 2016 60